GlassScriptPhysician profile
Jennifer A Clark
NPI 1629203948
$1,709.69
in general payments reported to CMS, 2019-2025
43 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $478 · 2023: $785 · 2024: $164 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $168.60 | 2022-2024 | Opdivo, Eliquis |
| Novartis Pharmaceuticals Corporation | $163.42 | 2023-2025 | |
| Daiichi Sankyo INC. | $117.71 | 2023-2025 | Enhertu, Injectafer |
| Pharmacyclics LLC, An Abbvie Company | $82.18 | 2022-2023 | Imbruvica |
| Janssen Pharmaceuticals, INC | $75.86 | 2021-2023 | Xarelto |
| Seagen INC. | $62.70 | 2022-2023 | Padcev, Tukysa |
| Regeneron Healthcare Solutions, INC. | $58.00 | 2021-2023 | Libtayo |
| Abbvie INC. | $54.50 | 2021-2023 | |
| Eisai INC. | $51.96 | 2022 | |
| Merck Sharp & Dohme LLC | $48.09 | 2022-2023 | Keytruda, Lynparza |
| Pfizer INC. | $46.88 | 2023 | |
| Glaxosmithkline, LLC. | $45.40 | 2022-2023 | Zejula, Jemperli |
| Genzyme Corporation | $44.49 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.33 | 2021-2022 | |
| Incyte Corporation | $40.83 | 2021-2023 | Jakafi |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.